HU201680B - Process for producing synergetic pharmaceutical compositions with antitumoural effect - Google Patents

Process for producing synergetic pharmaceutical compositions with antitumoural effect Download PDF

Info

Publication number
HU201680B
HU201680B HU885793A HU579384A HU201680B HU 201680 B HU201680 B HU 201680B HU 885793 A HU885793 A HU 885793A HU 579384 A HU579384 A HU 579384A HU 201680 B HU201680 B HU 201680B
Authority
HU
Hungary
Prior art keywords
htnf
tnf
cells
cell
ifn
Prior art date
Application number
HU885793A
Other languages
English (en)
Hungarian (hu)
Inventor
Lloyd J Old
Elizabeth Carswell Richards
Berish Rubin
Barbara D Williamson
Jay S Prendergast
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of HU201680B publication Critical patent/HU201680B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HU885793A 1983-06-27 1984-06-26 Process for producing synergetic pharmaceutical compositions with antitumoural effect HU201680B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50847283A 1983-06-27 1983-06-27

Publications (1)

Publication Number Publication Date
HU201680B true HU201680B (en) 1990-12-28

Family

ID=24022900

Family Applications (2)

Application Number Title Priority Date Filing Date
HU885793A HU201680B (en) 1983-06-27 1984-06-26 Process for producing synergetic pharmaceutical compositions with antitumoural effect
HU842470A HU197358B (en) 1983-06-27 1984-06-26 Process for producing human antitumour substance and pharmaceuticals comprising same

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU842470A HU197358B (en) 1983-06-27 1984-06-26 Process for producing human antitumour substance and pharmaceuticals comprising same

Country Status (15)

Country Link
EP (1) EP0131789A3 (en:Method)
JP (1) JPS6036420A (en:Method)
KR (1) KR850000528A (en:Method)
AU (1) AU587959B2 (en:Method)
CA (1) CA1265444A (en:Method)
DD (3) DD241271A5 (en:Method)
DK (1) DK311984A (en:Method)
ES (2) ES533767A0 (en:Method)
FI (1) FI842560A7 (en:Method)
GR (1) GR82260B (en:Method)
HU (2) HU201680B (en:Method)
NO (1) NO842572L (en:Method)
NZ (1) NZ208648A (en:Method)
PT (1) PT78773B (en:Method)
ZA (1) ZA844377B (en:Method)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
JPS59141519A (ja) * 1983-01-31 1984-08-14 Otsuka Pharmaceut Co Ltd 制ガン作用を有する蛋白質
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS60243018A (ja) * 1984-05-17 1985-12-03 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US6686455B1 (en) 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
GR851626B (en:Method) * 1984-07-05 1985-11-26 Genentech Inc
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
WO1986003751A2 (en) * 1984-12-21 1986-07-03 Biogen N.V. Purification, production and use of tumor necrosis factors
EP0205038A1 (en) * 1985-05-29 1986-12-17 Suntory Limited Polypeptide, process for preparing it, microorganism and pharmaceutical use
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
DE102012024749A1 (de) 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
GR851626B (en:Method) * 1984-07-05 1985-11-26 Genentech Inc

Also Published As

Publication number Publication date
CA1265444A (en) 1990-02-06
DD241271A5 (de) 1986-12-03
AU587959B2 (en) 1989-09-07
GR82260B (en:Method) 1984-12-13
DK311984D0 (da) 1984-06-26
EP0131789A3 (en) 1986-12-03
FI842560L (fi) 1984-12-28
ES8608885A1 (es) 1986-07-16
NZ208648A (en) 1989-07-27
DD241268A5 (de) 1986-12-03
EP0131789A2 (en) 1985-01-23
FI842560A7 (fi) 1984-12-28
DK311984A (da) 1984-12-28
DD229713A5 (de) 1985-11-13
FI842560A0 (fi) 1984-06-26
ES8603949A1 (es) 1986-01-01
ES545258A0 (es) 1986-07-16
ES533767A0 (es) 1986-01-01
KR850000528A (ko) 1985-02-27
PT78773A (en) 1984-07-01
JPS6036420A (ja) 1985-02-25
NO842572L (no) 1984-12-28
AU2933784A (en) 1985-01-03
HUT34775A (en) 1985-04-28
PT78773B (en) 1986-06-26
ZA844377B (en) 1985-05-29
HU197358B (en) 1989-03-28

Similar Documents

Publication Publication Date Title
HU201680B (en) Process for producing synergetic pharmaceutical compositions with antitumoural effect
JP3825467B2 (ja) インターロイキン―７を用いた選定免疫療法
Donohue et al. The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.
CA2205405C (en) Method for treating secondary immunodeficiency
EP0242233A2 (en) Lymphokines for use in the treatment of infections
HUT73463A (en) Agonists and antagonists of human interleukin-10
JPH10510147A (ja) 二次性免疫不全症の治療用薬剤の製造方法
HU215389B (hu) Eljárás hatóanyagként IL-4-et tartalmazó tömött tumorok kezelésére alkalmas gyógyszerkészítmények előállítására
JP2846629B2 (ja) 組換えコロニー刺激因子−１を含んで成る医薬組成物
EP0768889B1 (en) Cancer therapy using lymphotoxin
US5250296A (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5616554A (en) Immune-enhancing agent for therapeutic use in immunocompromised hosts
KR100222274B1 (ko) 결합되지 않은 mpl 수용체를 사용하여 혈소판 생산을 자극하기 위한 조성물 및 방법
US5635175A (en) Use of CSF-1 to treat viral infections
CA1290249C (en) COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
Fride et al. Immunoenhancing effects of alprazolam in mice
JPH06500558A (ja) 組み換えコロニー刺激因子―１の使用
US20070087968A1 (en) Methods to treat T-cell disorders using TISF
JP4414494B2 (ja) 白血球減少症の予防剤および治療剤
AU643245B2 (en) A pharmaceutical preparation for the maturation of prothymocytes
CA1056305A (en) Protein having thymus hormone-like activity
US5837229A (en) Uses of recombinant colony stimulating factor-1
EP1033997B1 (en) Method of mobilizing hematopoietic stem cells
IE914328A1 (en) Improvements in or relating to pharmaceutical compositions for the treatment of B-cell malignancies
Abe et al. and cyclophosphamide-treated mice

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee